Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A condition in which there is a deviation from or interruption of the normal coagulation properties of the blood.
Clinical Trials49 registered · 21 recruiting
Diagnosis
Biomarker and diagnostic research for blood coagulation disease has been reported in the published literature.
Research Landscape
Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.
49 clinical trials registered, 21 recruiting. Interventions under study include other interventions, drug therapy, medical devices, and procedural interventions. Pipeline includes 3 PHASE4, 3 PHASE3, 1 PHASE2. Research is sponsored by a mix of industry and academic institutions.
Diseases are connected by shared genes, phenotypes, therapeutic targets, and MONDO disease hierarchy. The Rare badge reflects Kisho's rarity classification — scored from authoritative sources including OMIM, Orphanet, orphan drug designations, clinical trial activity, and published prevalence data.
Comparative Evaluation of the Performance of Different Thromboplastin Reagents on Prothrombin Time and Factorial Assays in Situations of Isolated Extrinsic Pathway Factor Deficiency or Liver Damage.
Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure
Goal-directed vs. Empirical Tranexamic Acid Administrationin Cardiovascular Surgery
NA
Konkuk University Medical Center
RECRUITING
127 publications have been identified in PubMed for blood coagulation disease. Research spans Case Report / Case Series (30%), Basic Science / Preclinical (17%), and Epidemiology / Natural History (16%).
Research Type
Count
% of Total
Patient case studies
38
30%
Laboratory research
21
17%
Disease patterns and progression
20
16%
Clinical study results
19
15%
Research summaries
14
11%
Testing and diagnosis research
8
6%
New treatment approaches
7
6%
Recent Publications
National Clinical Research Center for Infectious Diseases (2026). [PMID: 42209158](https://pubmed.ncbi.nlm.nih.gov/42209158/). *Zhonghua Gan Zang Bing Za Zhi*. [Review / Meta-Analysis]
Mao X (2026). [PMID: 41933331](https://pubmed.ncbi.nlm.nih.gov/41933331/). *Thromb J*. [Case Report / Case Series]
Kailera Therapeutics, Nektar Therapeutics, and Hemab Therapeutics bagged the biggest biotech funding rounds overall in April 2026. The companies Kailera Therapeutics, Nektar Therapeutics, and Hemab Therapeutics bagged the biggest biotech funding rounds overall in April 2026 across private and public funding types. Naturally, Kailera’s huge $625 million IPO round meant that metabolic diseases was the therapeutic subsector that brought in the most money. Below is a graph showing a month-to-month comparison of private and public biotech fundraising, looking at the total amount of money raised per month in 2026. Already known for bringing in huge private fundraising rounds, Kailera Therapeutics continued that trend as it went public, pricing an incredible $625 million initial public offering (IPO) last month. The company is advancing a pipeline of next-generation obesity treatments. In second place was Nektar Therapeutics, which priced a $325 million public offering as it works on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases, and, in third spot, was Hemab Therapeutics, which priced a $301.5 million IPO to fund therapies that it says “reimagine” the treatment of blood coagulation disorders. First, let’s take a look at the private biotech investments in April 2026, breaking them down by value, location, funding type, and therapeutic subsector. April 2026 saw Beeline Medicines debut with a very impressive $300 million in series A funding to develop and deliver “category-leading” precision therapies to transform the lives of people with autoimmune and inflammatory diseases.
